1. Department of Pediatrics,
2. Cell Therapy and Transplantation Medicine,
3. Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
4. Division of Functional Genomics, Jichi Medical University, Toguchi 329-0498, Japan
5. Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
6. Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, 332-0012, Japan
7. Division of Hematology/Oncology, Saitama Children's Medical Center, Saitama 339-8551, Japan
8. Gunma Children's Medical Center, Shibukawa 377-8577, Japan
9. These authors contributed equally to this work.

Correspondence to: Yasuhide Hayashi⁸Seishi Ogawa^2,3,6 Correspondence and requests for materials should be addressed to S.O. (Email: sogawa-tky@umin.net) or Y.H. (Email: hayashiy-tky@umin.ac.jp).

Abstract

Neuroblastoma in advanced stages is one of the most intractable paediatric cancers, even with recent therapeutic advances¹. Neuroblastoma harbours a variety of genetic changes, including a high frequency of MYCN amplification, loss of heterozygosity at 1p36 and 11q, and gain of genetic material from 17q, all of which have been implicated in the pathogenesis of neuroblastoma^{2, 3, 4, 5}. However, the scarcity of reliable molecular targets has hampered the development of effective therapeutic agents targeting neuroblastoma. Here we show that the anaplastic lymphoma kinase (ALK), originally identified as a fusion kinase in a subtype of non-Hodgkin's lymphoma (NPM–ALK)^{6, 7, 8} and more recently in adenocarcinoma of lung (EML4–ALK)^{9, 10}, is also a frequent target of genetic alteration in advanced neuroblastoma. According to our genome-wide scans of genetic lesions in 215 primary neuroblastoma samples using high-density single-nucleotide polymorphism genotyping microarrays^{11, 12, 13, 14}, the ALK locus, centromeric to the MYCN locus, was identified as a recurrent target of copy number gain and gene amplification. Furthermore, DNA sequencing of ALK revealed eight novel missense mutations in 13 out of 215 (6.1%) fresh tumours and 8 out of 24 (33%) neuroblastoma-derived cell lines. All but one mutation in the primary samples (12 out of 13) were found in stages 3–4 of the disease and were harboured in the kinase domain. The mutated kinases were autophosphorylated and displayed increased kinase activity compared with the wild-type kinase. They were able to transform NIH3T3 fibroblasts as shown by their colony formation ability in soft agar and their capacity to form tumours in nude mice. Furthermore, we demonstrate that downregulation of ALK through RNA interference suppresses proliferation of neuroblastoma cells harbouring mutated ALK. We anticipate that our findings will provide new insights into the pathogenesis of advanced neuroblastoma and that ALK-specific kinase inhibitors might improve its clinical outcome.

1. Department of Pediatrics,
2. Cell Therapy and Transplantation Medicine,
3. Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
4. Division of Functional Genomics, Jichi Medical University, Toguchi 329-0498, Japan
5. Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
6. Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, 332-0012, Japan
7. Division of Hematology/Oncology, Saitama Children's Medical Center, Saitama 339-8551, Japan
8. Gunma Children's Medical Center, Shibukawa 377-8577, Japan
9. These authors contributed equally to this work.

Correspondence to: Yasuhide Hayashi⁸Seishi Ogawa^2,3,6 Correspondence and requests for materials should be addressed to S.O. (Email: sogawa-tky@umin.net) or Y.H. (Email: hayashiy-tky@umin.ac.jp).

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.